Adarx Pharmaceuticals ADRX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$86.1K (10 inflow days, 10 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 52.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 1.14% to 1.76% of float over the last 3 biweekly reports (30 Sep 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +24,794,024 | 22.1% |
| Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | VC/PE Fund | 2026/Q3 | +11,858,655 | 10.6% |
| FMR | Mutual Fund | 2026/Q3 | +3,646,090 | 3.3% |
| Capital Research | Mutual Fund | 2026/Q3 | +3,332,301 | 3.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +2,336,110 | 2.1% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +1,962,004 | 1.8% |
| Artal Group S.A. | VC/PE Fund | 2026/Q3 | +1,925,794 | 1.7% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +900,000 | 0.8% |
| MFS Investment Management | Mutual Fund | 2026/Q3 | +650,360 | 0.6% |
| abrdn plc | Mutual Fund | 2026/Q3 | +120,000 | 0.1% |
| TD Asset Management | Mutual Fund | 2026/Q3 | +91,770 | 0.1% |
| Jane Street Group, LLC | Private Company | 2026/Q3 | +63,680 | 0.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +43,331 | 0.0% |
| Morgan Stanley | Public Company | 2026/Q3 | +22,544 | 0.0% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +22,544 | 0.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 27 Sep 2026 | OrbiMed Advisors LLC | Private Acquisition | +950,000 | $17.00 | 24,205,789 | |
| 27 Sep 2026 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +23,255,789 | – | 24,205,789 | |
| 27 Sep 2026 | Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | Derivative Exercise and Retained | +11,858,655 | – | 11,858,655 | |
| 27 Sep 2026 | SR One Capital Management, LP | Private Acquisition | +1,600,000 | $17.00 | 9,936,661 | |
| 27 Sep 2026 | SR One Capital Management, LP | Derivative Exercise and Retained | +8,336,661 | – | 9,936,661 | |
| 23 Sep 2026 | Mary Tagliaferri | Independent Director | Initial Statement of Beneficial | +0 | – | 357,056 |
| 23 Sep 2026 | Ying Huang | Independent Director | Initial Statement of Beneficial | +0 | – | 267,792 |
| 23 Sep 2026 | Li Zhen | Chief Executive Officer | Other Derivative Acquisition | +1,024,152 | $17.00 | 1,024,152 |
| 23 Sep 2026 | Li Zhen | Chief Executive Officer | Initial Statement of Beneficial | +0 | – | 5,960,786 |
| 23 Sep 2026 | Robert Ackles | Chief Human Resources Officer | Other Derivative Acquisition | +85,346 | $17.00 | 85,346 |
| 23 Sep 2026 | Robert Ackles | Chief Human Resources Officer | Initial Statement of Beneficial | +0 | – | 335,633 |
| 23 Sep 2026 | A. MacLeod | Chief Scientific Officer | Other Derivative Acquisition | +170,692 | $17.00 | 170,692 |
| 23 Sep 2026 | A. MacLeod | Chief Scientific Officer | Initial Statement of Beneficial | +0 | – | 667,023 |
| 23 Sep 2026 | Ryan Fisk | CFO & Chief Business Officer | Other Derivative Acquisition | +170,692 | $17.00 | 170,692 |
| 23 Sep 2026 | Ryan Fisk | CFO & Chief Business Officer | Initial Statement of Beneficial | +0 | – | 865,864 |
| 23 Sep 2026 | Rui Zhu | Chief Technology Officer | Other Derivative Acquisition | +512,076 | $17.00 | 512,076 |
| 23 Sep 2026 | Rui Zhu | Chief Technology Officer | Initial Statement of Beneficial | +0 | – | 1,277,859 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 1,801,373 | 1.8% | 5.0 |
| 15 Oct 2026 | 1,903,521 | 1.9% | 3.1 |
| 30 Sep 2026 | 1,163,375 | 1.1% | 1.7 |
No comments yet — be the first to weigh in on ADRX.
Sign in to join the discussion.